New-onset depression among children, adolescents, and adults with hidradenitis suppurativa - 10/10/20
Abstract |
Background |
Information on the risk of depression among children, adolescents, and adults with hidradenitis suppurativa (HS) is limited.
Objective |
To compare the risk of new-onset depression in patients with HS with that of control individuals.
Methods |
Retrospective cohort analysis of 49,280 adult and 3042 pediatric patients with HS and matched control individuals identified by using electronic health record data. The primary outcome was incident depression.
Results |
The crude incidence rate was 4.8 per 100 person-years in adult patients with HS compared to 3.0 per 100 person-years in control individuals. Among pediatric patients, the crude incidence rate was 4.2 per 100 person-years in patients with HS compared with 2.3 per 100 person-years in control individuals. In adjusted analysis, adults and pediatric patients with HS had a 10% (hazard ratio, 1.10; 95% confidence interval, 1.07-1.13; P < .001) and 26% (hazard ratio, 1.26; 95% confidence interval, 1.10-1.44; P < .001), respectively, increased risk of developing depression compared to control individuals. Among patients with HS, factors associated with depression included female sex, white race, smoking, and body mass index/obesity in adults and pediatric patients and substance abuse in adults only.
Limitations |
Patients not seeking care in health systems within the database were not captured.
Conclusion |
Children, adolescents, and adults with HS are at an increased risk for developing depression, independent of other common risk factors for depression.
Le texte complet de cet article est disponible en PDF.Key words : comorbidity, depression, Explorys, hidradenitis suppurativa, incidence, mood disorder, new-onset
Abbreviations used : BMI, CI, HR, HS, ICD
Plan
| Funding sources: Supported in part by an education grant from AbbVie. AbbVie had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
| Disclosure: Dr Garg has served as an advisor for AbbVie, Amgen, Boehringer Ingelheim, Janssen, Pfizer, Incyte, Viela Bio, and UCB and has received honoraria. Authors Wright and Strunk have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the human subjects committee at the Feinstein Institutes for Medical Research at Northwell Health. |
|
| Reprints not available from the authors. |
Vol 83 - N° 5
P. 1360-1366 - novembre 2020 Retour au numéro
Article précédent
- Association of atopic dermatitis severity with cognitive function in adults
- Jonathan I. Silverberg, Donald Lei, Muhammad Yousaf, Sherief R. Janmohamed, Paras P. Vakharia, Rishi Chopra, Rajeev Chavda, Sylvie Gabriel, Kevin R. Patel, Vivek Singam, Robert Kantor, Derek Y. Hsu, David Cella
- Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
- Andrew Blauvelt, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Nancy Cross, Cynthia Madden, Maggie Wang, Christopher Cioffi, Christopher E.M. Griffiths
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?